Syneron Medical says Syneron Beauty poised to break even in 1Q, says Cantor After meeting with Syneron's management, Cantor reports that the company expects its Syneron Beauty segment to break even this quarter. The firm thinks the company is poised to report "meaningful profitability" this year, and it reiterates a $16 price target and Buy rating on the stock.
News For ELOS From The Last 14 Days
Check below for free stories on ELOS the last two weeks.
Syneron Medical recommend following FDA clearance at Maxim Maxim recommends investors continue buying shares of Syneron Medical following the FDA clearance of UltraShape. Maxim says UltraShape expands the base of body shaping treatments that physicians may use with complimentary Syneron systems and it keeps a Buy rating on the stock with a $16 price target.